Pasar al contenido principal

RENDIMIENTO DE LA RM CON ACIDO GADOXETICO PARA EL DIAGNOSTICO Y ESTADIAJE DEL CARCINOMA HEPATOCELULAR: CORRELACION RADIOLOGICA-PATOLOGICA

PI18/00542

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2018
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)
Centro realización INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma

  • Pinato, David James|||0000-0002-3529-0103
  • Kaneko, Takahiro
  • D'Alessio, Antonio
  • Forner, Alejandro|||0000-0002-9014-4950
  • Fessas, Petros|||0000-0002-7472-8913
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Giannini, Edoardo G.
  • Grillo, Federica
  • Díaz, Alba|||0000-0002-0456-7085
  • Mauri, Francesco A.
  • Fulgenzi, Claudia A.M.
  • Dalla Pria, Alessia
  • Goldin, Robert D.
  • Pieri, Giulia
  • Toniutto, Pierluigi|||0000-0002-2566-3041
  • Avellini, Claudio
  • Plaz Torres, Maria Corina
  • Akarca, Ayse U.
  • Marafioti, Teresa
  • Bhoori, Sherrie
  • Miró, José M.|||0000-0001-8057-7755
  • Bower, Mark
  • Bräu, Norbert
  • Mazzaferro, Vincenzo|||0000-0002-4013-8085
HIV-seropositivity shortens survival in patients with hepatocellular carcinoma (HCC). Although risk factors for HCC including HCV infection can influence T cell phenotype, it is unknown whether HIV can influence functional characteristics of the T cell infiltrate. From the Liver Cancer in HIV biorepository, we derived 129 samples of transplanted (76%) or resected (20%) HCC in eight European and North American centres. We profiled intra- and peritumoural tissue to evaluate regulatory CD4+/FOXP3+ and immune-exhausted CD8+/PD1+ T cells in HIV+ (n = 66) and HIV- (n = 63) samples. We performed targeted transcriptomics and T-cell receptor sequencing in a restricted subset of samples evaluated in relationship with HIV status. We correlated immunopathologic features with patients' characteristics including markers of HIV infection. Of the 66 HIV+ patients, 83% were HCV coinfected with an undetectable HIV viral load (51%) and a median blood CD4+ cell count of 430 cells/mm 3 (range 15-908). Patients who were HIV+ were compared with HIV- controls with similar staging characteristics including Barcelona Clinic Liver Cancer (BCLC) stage A-B (86% vs. 83%, p = 0.16), <3 nodules (90% vs. 83%, p = 0.3) and median alpha-foetoprotein values (10.9 vs. 12.8 ng/ml, p = 0.72). HIV+ samples had higher PD-L1 expression rates in tumour tissue (51% vs. 8% p <0.0001) and displayed denser intratumoural CD4+/FOXP3+ (p <0.0001), CD8+/PD1+ (p <0.0001), with lower total peritumoural CD4+ (p <0.0001) and higher peritumoural CD8+/PD1+ (p <0.0001). Gene set analysis revealed HIV+ cases to have evidence of dysregulated adaptive and innate immunity. Tumour-infiltrating lymphocyte clonality was not influenced by HIV status. HIV-associated HCC harbours a profoundly immune-exhausted tumour microenvironment, warranting prospective testing of immunotherapy in this treatment-deprived patient population. Hepatocellular carcinoma is a non-AIDS defining malignancy characterised by poor survival. The programmed cell death (PD-1) pathway governs antiviral and anticancer immune exhaustion and is a therapeutic target in HCC. This study highlights how HIV infection is associated with significantly higher PD-L1 expression in HCC cells and in the surrounding microenvironment, leading to changes in cytotoxic and regulatory T cell function and dysregulation of proinflammatory pathways. Taken together, our results suggest dysfunctional T cell immunity as a mechanism of worse outcome in these patients and suggest clinical testing of checkpoint inhibitors in HIV-associated HCC.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma, implications for immunotherapy.

  • Pinato, David James|||0000-0002-3529-0103
  • Murray, Sam M.
  • Forner, Alejandro|||0000-0002-9014-4950
  • Kaneko, Takahiro
  • Fessas, Petros|||0000-0002-7472-8913
  • Toniutto, Pierluigi|||0000-0002-2566-3041
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Cacciato, Valentina
  • Avellini, Claudio
  • Díaz, Alba|||0000-0002-0456-7085
  • Boyton, Rosemary J.
  • Altmann, Daniel M.
  • Goldin, Robert D.
  • Akarca, Ayse U.
  • Marafioti, Teresa
  • Mauri, Francesco A.
  • Casagrande, Edoardo
  • Grillo, Federica
  • Giannini, Edoardo
  • Bhoori, Sherrie
  • Mazzaferro, Vincenzo|||0000-0002-4013-8085
Modulation of adaptive immunity may underscore the efficacy of trans-arterial chemoembolization (TACE). We evaluated the influence of TACE on T-cell function by phenotypic lymphocyte characterization in samples of patients undergoing surgery with (T+) or without (T-) prior-TACE treatment. We profiled intratumoral (IT), peritumoral (PT) and non-tumoral (NT) background tissue to evaluate regulatory CD4+/FOXP3+ (T-reg) and immune-exhausted CD8+/PD-1+ T-cells across T+ (n=58) and T- (n=61). We performed targeted transcriptomics and T-cell receptor sequencing in a restricted subset of samples (n=24) evaluated in relationship with the expression of actionable drivers of anti-cancer immunity including PD-L1, indoleamine 2,3 dehydrogenase (IDO-1), cytotoxic T-lymphocyte associated protein 4 (CTLA-4), Lag-3, Tim-3 and CD163. We analyzed 119 patients resected (n=25, 21%) or transplanted (n=94, 79%) for Child-Pugh A (n=65, 55%) and Barcelona Clinic Liver Cancer stage A (n=92, 77%) hepatocellular carcinoma. T+ samples displayed lower IT CD4+/FOXP3+ (p=0.006), CD8+ (p=0.002) and CD8+/PD-1+ and NT CD8+/PD-1+ (p<0.001) compared with T-. Lower IT (p=0.005) and NT CD4+/FOXP3+ (p=0.03) predicted for improved recurrence-free survival. In a subset of samples (n=24), transcriptomic analysis revealed upregulation of a pro-inflammatory response in T+. T+ samples were enriched for IRF2 expression (p=0.01), an interferon-regulated transcription factor implicated in cancer immune-evasion. T-cell clonality and expression of PD-L1, IDO-1, CTLA-4, Lag-3, Tim-3 and CD163 was similar in T+ versus T-. TACE is associated with lower IT density of immune-exhausted effector cytotoxic and T-regs, with significant upregulation of pro-inflammatory pathways. This highlights the pleiotropic effects of TACE in modulating the tumor microenvironment and strengthens the rationale for developing immunotherapy alongside TACE.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Risk of Treatment Failure and Death after Ablation in Hepatocellular Carcinoma Patients-A Multiparametric Prediction

  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Sapena, Victor|||0000-0003-4379-6486
  • García Criado, Ángeles|||0000-0003-3536-4288
  • Darnell, Anna
  • Forner, Alejandro|||0000-0002-9014-4950
  • Belmonte, Ernest|||0000-0003-3572-9769
  • Sanduzzi Zamparelli, Marco|||0000-0003-3795-3705
  • Rimola, Jordi|||0000-0002-1814-4198
  • Soler-Perromat, Alexandre|||0000-0003-2531-2484
  • Llarch, Neus|||0000-0003-3209-0453
  • Iserte, Gemma|||0000-0003-3908-8743
  • Mauro, Ezequiel|||0000-0002-0757-7676
  • Ayuso, Carmen|||0000-0002-9606-6957
  • Ríos, José|||0000-0002-0716-8784
  • Bruix, Jordi|||0000-0002-9826-0753
  • Vilana, Ramon|||0000-0002-2249-1926
  • Reig, María|||0000-0002-5711-9534
Background: Ablation is a first-line treatment for Barcelona Clinic Liver Cancer (BCLC)-0/A hepatocellular carcinoma (HCC). However, there are scarce data about patients' outcomes after recurrence. The present study evaluates the impact of patient and tumor characteristics at baseline and at recurrence on the Clinical Decision-Making process. Methods: We evaluated BCLC-0/A patients treated with percutaneous ablation from January 2010 to November 2018. Clinical and radiological data such as age, tumor location at ablation, pattern of recurrence/progression, and comorbidities during follow-up were registered. Tumor location was divided into 'suboptimal' vs. 'optimal' locations for ablation. The Clinical Decision-Making was based on tumor burden, liver dysfunction, or comorbidities. The statistical analysis included the time-to-recurrence/progression, censoring at time of death, date of last follow-up or liver transplantation, and time-to-event was estimated by the Kaplan-Meier method and Cox regression models to evaluate the risk of an event of death and change of treatment strategy. Results: A total of 225 patients [39.1% BCLC-0 and 60.9% BCLC-A] were included, 190 had unifocal HCC and 82.6% were ≤3 cm. The complete response rate and median overall survival were 96% and 60.7 months. The HCC nodules number (Hazard Ratio-HR 3.1), Child-Pugh (HR 2.4), and Albumin-Bilirubin score (HR 3.2) were associated with increased risk of death during follow-up. HCC in 'suboptimal location' presented a shorter time to recurrence. When comorbidities prevented further loco-regional or systemic treatment, the risk of death was significantly increased (HR 2.0, p = 0.0369) in comparison to those who received treatment. Conclusions: These results expose the impact of non-liver comorbidities when considering treatment for recurrence after ablation in the real-world setting and in research trials. Ultimately, we identified an orphan population for which effective interventions are needed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma

  • Corominas Argente del Castillo, Josep|||0000-0002-5351-9469
  • Sapena, Victor|||0000-0003-4379-6486
  • Sanduzzi Zamparelli, Marco|||0000-0003-3795-3705
  • Millán, Cristina
  • Samper, Esther
  • Llarch, Neus|||0000-0003-3209-0453
  • Iserte, Gemma|||0000-0003-3908-8743
  • Torres, Ferran|||0000-0002-7355-7913
  • Da Fonseca, Leonardo G.|||0000-0002-0216-3618
  • Muñoz-Martínez, S|||0000-0003-0663-0575
  • Forner, Alejandro|||0000-0002-9014-4950
  • Bruix, Jordi|||0000-0002-9826-0753
  • Boix, Loreto|||0000-0002-6015-3901
  • Reig, María|||0000-0002-5711-9534
Hepatocellular carcinoma is the second cause of cancer-related death worldwide. Of those advanced-stage patients who are treated with sorafenib, those who develop early dermatologic adverse events have a better prognosis. These events are possibly immune-related. Therefore, we analyzed the phenotype of 52 sorafenib-treated patients' circulating lymphocytes throughout treatment. We found that different co-stimulatory and immune exhaustion markers, such as Programmed cell death protein 1 (PD-1) and DNAX accessory molecule 1 (DNAM-1) amongst others, correlate with the probability of developing these adverse events, both before and during the treatment. We also compared the phenotype of those lymphocytes expressing DNAM-1 with those that do not, and while NK DNAM-1-expressing cells have a co-stimulatory phenotype, T DNAM-1-expressing cells are immune-suppressors. Overall, we set a rationale for the combination of sorafenib and immune-targeted therapies; and for the use of immune markers (such as DNAM-1) for patients' prognosis evaluation. Advanced hepatocellular carcinoma patients treated with sorafenib who develop early dermatologic adverse events (eDAEs) have a better prognosis. This may be linked to immune mechanisms, and thus, it is relevant to assess the association between peripheral immunity and the probability of developing eDAEs. Peripheral blood mononuclear cells of 52 HCC patients treated with sorafenib were analyzed at baseline and throughout the first eight weeks of therapy. T, B, Natural Killer cells, and their immune checkpoints expression data were characterized by flow cytometry. Cytokine release and immune-suppression assays were carried out ex vivo. Cox baseline and time-dependent regression models were applied to evaluate the probability of increased risk of eDAEs. DNAM-1, PD-1, CD69, and LAG-3 in T cells, plus CD16 and LAG-3 in NK cells, are significantly associated with the probability of developing eDAEs. While NK DNAM-1 + cells express activation markers, T DNAM-1 + cells induce immune suppression and show immune exhaustion. This is the first study to report an association between immune checkpoints expression in circulating immune cells and the increased incidence of eDAEs. Our results support the hypothesis for an off-target role of sorafenib in immune modulation. We also describe a novel association between DNAM-1 and immune exhaustion in T cells.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs

  • Díaz-González, Álvaro|||0000-0003-3610-2263
  • Sapena, Victor|||0000-0003-4379-6486
  • Boix, Loreto|||0000-0002-6015-3901
  • Torres, Ferran|||0000-0002-7355-7913
  • Sanduzzi Zamparelli, Marco|||0000-0003-3795-3705
  • Da Fonseca, Leonardo G.|||0000-0002-0216-3618
  • Llarch, Neus|||0000-0003-3209-0453
  • Iserte, Gemma|||0000-0003-3908-8743
  • Guedes, Cassia
  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Darnell, Anna
  • Belmonte, Ernest|||0000-0003-3572-9769
  • Rimola, Jordi|||0000-0002-1814-4198
  • Forner, Alejandro|||0000-0002-9014-4950
  • Ayuso, Carmen|||0000-0002-9606-6957
  • Bruix, Jordi|||0000-0002-9826-0753
  • Reig, María|||0000-0002-5711-9534
Despite atezolizumab and bevacizumab (A + B) is currently the first-line treatment for hepatocellular carcinoma (HCC) patients, some patients will not be adequate for this combination. In the setting of sorafenib some adverse events have been proposed as prognostic factors. To characterize the early diarrhoea development as prognostic factor in 344 HCC patients. The development of early diarrhoea in sorafenib treatment defined as patients who developed diarrhoea and needed dose modification within the first 60 days of treatment (e-diarrhoea) and 3-grouping variables were analysed: Patients with e-diarrhoea, patients who developed diarrhoea after the first 60 days of treatment (L-diarrhoea) and patients that never developed diarrhoea (never diarrhoea). The median overall survival in sorafenib treated patients was significantly different across groups (6.8 months for e-diarrhoea, 26.7 months for L-diarrhoea and 13.3 months for never-diarrhoea). The emergence of e-diarrhoea was associated with poor outcomes (hazard ratio [HR] 1.84 [95%CI 1.15-2.95]), while there was no increased/decreased risk of dismal evolution in patients with L-diarrhoea (HR 0.66 [95%CI 0.42-1.03]). The emergence of e-diarrhoea in HCC patients treated with sorafenib is an early predictor of dismal evolution under this therapy. Thus, prompt identification of these non-responders may be useful for an early switch to second-line therapies. Established knowledge on this subject What are the significant and/or new findings of this study?.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Outcome of liver cancer patients with SARS-CoV-2 infection, An International, Multicentre, Cohort Study

  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Sapena, Victor|||0000-0003-4379-6486
  • Forner, Alejandro|||0000-0002-9014-4950
  • Bruix, Jordi|||0000-0002-9826-0753
  • Sanduzzi Zamparelli, Marco|||0000-0003-3795-3705
  • Ríos, José|||0000-0002-0716-8784
  • Bouattour, Mohamed|||0000-0002-3919-4135
  • El-Kassas, Mohamed|||0000-0002-3396-6894
  • Leal, Cassia R. G.
  • Mocan, Tudor|||0000-0001-7785-6403
  • Nault, Jean-Charles|||0000-0002-4875-9353
  • Alves, Rogerio C. P.
  • Reeves, Helen L.|||0000-0003-0359-9795
  • Da Fonseca, Leonardo G.|||0000-0002-0216-3618
  • García-Juárez, Ignacio|||0000-0003-2400-1887
  • Pinato, David James|||0000-0002-3529-0103
  • Varela Calvo, Maria|||0000-0003-4288-2593
  • Alqahtani, Saleh|||0000-0003-2017-3526
  • Alvares-da-Silva, Mario R.|||0000-0002-5001-246X
  • Bandi, Juan C.|||0000-0001-9733-1938
  • Rimassa, Lorenza|||0000-0001-9957-3615
  • Lozano, Mar|||0000-0001-7099-0810
  • González Santiago, Jesús M.|||0000-0003-4667-4492
  • Tacke, Frank|||0000-0001-6206-0226
  • Sala, Margarita
  • Anders, María|||0000-0002-2238-5322
  • Lachenmayer, Anja|||0000-0002-5879-5737
  • Piñero, Federico
  • França, Alex
  • Guarino, Maria|||0000-0002-0460-4122
  • Elvevi, Alessandra
  • Cabibbo, Giuseppe|||0000-0002-0946-3859
  • Peck-Radosavljevic, Markus|||0000-0002-0597-2728
  • Rojas, Ángela|||0000-0003-0853-4800
  • Vergara, Mercedes|||0000-0002-6971-8657
  • Braconi, Chiara|||0000-0003-4835-1259
  • Pascual, Sonia|||0000-0002-4265-5019
  • Perelló, Christie|||0000-0003-0234-2330
  • Mello, Vivianne
  • Rodríguez Lope, Carlos|||0000-0002-6713-8800
  • Acevedo, Juan|||0000-0003-4507-2422
  • Villani, Rosanna|||0000-0001-9875-019X
  • Hollande, Clemence|||0000-0002-2287-0635
  • Vilgrain, Valérie
  • Tawheed, Ahmed|||0000-0002-9382-8733
  • Ferguson Theodoro, Carmem|||0000-0001-6605-1060
  • Sparchez, Zeno
  • Blaise, Lorraine
  • Viera-Alves, Daniele E.
  • Watson, Robyn
  • Carrilho, Flair J.
  • Moctezuma-Velázquez, Carlos|||0000-0003-2367-2742
  • D'Alessio, Antonio
  • Iavarone, Massimo|||0000-0003-3493-6504
  • Reig, María|||0000-0002-5711-9534
Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population. Multicentre retrospective, cross-sectional, international study of liver cancer patients with SARS-CoV-2 infection registered between February and December 2020. Clinical data at SARS-CoV-2 diagnosis and outcomes were registered. Two hundred fifty patients from 38 centres were included, 218 with hepatocellular carcinoma (HCC) and 32 with intrahepatic cholangiocarcinoma (iCCA). The median age was 66.5 and 64.5 years, and 84.9% and 21.9% had cirrhosis in the HCC and iCCA cohorts respectively. Patients had advanced cancer stage at SARS-CoV-2 diagnosis in 39.0% of the HCC and 71.9% of the iCCA patients. After a median follow-up of 7.20 (IQR: 1.84-11.24) months, 100 (40%) patients have died, 48% of the deaths were SARS-CoV-2-related. Forty (18.4%) HCC patients died within 30-days. The death rate increase was significantly different according to the BCLC stage (6.10% [95% CI 2.24-12.74], 11.76% [95% CI 4.73-22.30], 20.69% [95% CI 11.35-31.96] and 34.52% [95% CI 17.03-52.78] for BCLC 0/A, B, C and D, respectively; p =.0017). The hazard ratio was 1.45 (95% CI 0.49-4.31; p =.5032) in BCLC-B versus 0/A, and 3.13 (95% CI 1.29-7.62; p =.0118) in BCLC-C versus 0/A in the competing risk Cox regression model. Nineteen out of 32 iCCA (59.4%) died, and 12 deaths were related to SARS-CoV-2 infection. This is the largest cohort of liver cancer patients infected with SARS-CoV-2. It characterizes the 30-day mortality risk of SARS-CoV-2 infected patients with HCC during this period.